Technology Opportunities

B11 is effective in treating inflammatory diseases with no side effects

Highlights

• The B11 peptide is an epitope mimic of mycobacterial lipoglycan mannosylated lipoarabinomannan (ManLAM). B11 peptide demonstrates anti-inflammatory properties in several in vivo models (allergic asthma, EAE and colitis).
• Main advantages:
• Peptides are easier to manufacture than the complex mycobacterial lipoglycan.
• Manufacturing of peptides is highly reproducible.
• Peptides can be produced under good manufacturing practice (GMP).
• Main results: B11 peptide reduces inflammation symptoms in murine models of allergic asthma (ovalbumine induced allergic peritonitis and allergic asthma), EAE, and colitis (TNBS, DSS models).
• Scope of the technology: A peptide with immuno-modulatory properties similar to the natural complex lipoglycan ManLAM.

Our Innovation (facts and advantages)

• B11 peptide not only mimics the antigenic epitope of ManLAM but has also has similar immuno-regulatory properties.
• Key features: An anti-inflammatory drug, small peptide derived drug, and non toxic at therapeutical doses.
• Key benefits: Non steroid anti-inflammatory peptide, easy to manufacture and highly reproducible.
• Mechanism of action: B11 peptide mimics mycobacterial lipoglycan (ManLAM). ManLAM is produced by mycobacteria and is a natural immuno-modulator of macrophage and dendritic cells and suppresses allergic asthma in murine models. B11 peptide has similar properties.
• Proof of concept: The immuno-modulatory properties of the B11 peptide were demonstrated on macrophage cell cultures. Anti-inflammatory properties were shown in murine inflammation models (allergic asthma, EAE and colitis).

The opportunity

• Inflammatory diseases such as allergic asthma and colitis are a major health problem in the western world with increasing rates.
• Corticosteroids are the most effective treatment used, but cause many side effects.
• B11 peptide is a non steroidal anti-inflammatory molecule.

Development Milestones

• Pharmacokinetics, stability, doses responses, advanced toxicity.
• 1 million US $ in 2 years.